Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SECURE: Mepolizumab Administration Methods in Severe Asthma
NCT05626777Phase 4Active, not recruiting
- Sponsor
- Hospices Civils de Lyon
- Start
- Mar 2023
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of mepolizumab in asthma (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Asthma Control at 6 months. Started Mar 2023; status: active, not recruiting.
02
Drugs
mepolizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05626777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05626777.